Selected article for: "acute respiratory syndrome and adequately manage"
Author: Rahmawati, Putu Lohita; Tini, Kumara; Susilawathi, Ni Made; Wijayanti, IA Sri; Samatra, DPG Purwa
Title: Pathomechanism and Management of Stroke in COVID-19: Review of Immunopathogenesis, Coagulopathy, Endothelial Dysfunction, and Downregulation of ACE2
  • Cord-id: cf8n9dg8
  • Document date: 2021_3_18
    • ID: cf8n9dg8
    Snippet: Coronavirus disease 2019 (COVID-19) can reportedly manifest as an acute stroke, with most cases presenting as large vessel ischemic stroke in patients with or without comorbidities. The exact pathomechanism of stroke in COVID-19 remains ambiguous. The findings of previous studies indicate that the most likely underlying mechanisms are cerebrovascular pathological conditions following viral infection, inflammation-induced endothelial dysfunction, and hypercoagulability. Acute endothelial damage d
    Document: Coronavirus disease 2019 (COVID-19) can reportedly manifest as an acute stroke, with most cases presenting as large vessel ischemic stroke in patients with or without comorbidities. The exact pathomechanism of stroke in COVID-19 remains ambiguous. The findings of previous studies indicate that the most likely underlying mechanisms are cerebrovascular pathological conditions following viral infection, inflammation-induced endothelial dysfunction, and hypercoagulability. Acute endothelial damage due to inflammation triggers a coagulation cascade, thrombosis propagation, and destabilization of atherosclerosis plaques, leading to large-vessel occlusion and plaque ulceration with concomitant thromboemboli, and manifests as ischemic stroke. Another possible mechanism is the downregulation of angiotensin-converting enzyme 2 as the target action of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Acute stroke management protocols need to be modified during the COVID-19 pandemic in order to adequately manage stroke patients with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • ace angiotensin and acute management: 1, 2, 3, 4, 5
    • ace angiotensin and acute phase: 1, 2, 3, 4, 5
    • ace angiotensin and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • ace angiotensin and acute st elevation myocardial infarction: 1
    • ace angiotensin and acute stroke: 1, 2, 3, 4
    • ace angiotensin and acute stroke management: 1
    • ace angiotensin and lmwh molecular weight heparin: 1
    • ace angiotensin and low lmwh molecular weight heparin: 1
    • ace angiotensin and low mortality: 1, 2
    • ace angiotensin and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • ace angiotensin ii and activation production: 1, 2, 3
    • ace angiotensin ii and acute management: 1, 2
    • ace angiotensin ii and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • ace angiotensin ii and low mortality: 1, 2
    • ace angiotensin ii and lung tissue: 1, 2, 3, 4, 5, 6
    • ace inhibition and activation production: 1
    • ace inhibition and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5
    • ace inhibition and lung tissue: 1, 2, 3